Alison Armour
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Oncology top 0.2%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 19
- Prostate Cancer Treatment and Research 5
- Oncology 16
- Colorectal Cancer Treatments and Studies 9
- Lung Cancer Research Studies 6
- HER2/EGFR in Cancer Research 3
- Co-authors
- Tony Mok (5 shared papers)Yi‐Long Wu (4 shared papers)Emma Duffield (8 shared papers)Claire Watkins (5 shared papers)Masahiro Fukuoka (5 shared papers)Haiyi Jiang (3 shared papers)Nagahiro Saijo (5 shared papers)Sumitra Thongprasert (3 shared papers)
- Journals
- Journal of Clinical Oncology (13 papers)Annals of Oncology (4 papers)Journal of Thoracic Oncology (3 papers)Cancer Research (2 papers)New England Journal of Medicine (2 papers)
- Partner nations
- United KingdomUnited StatesChina
In The Last Decade
Alison Armour
37 papers receiving 11.5k citations
Alison Armour's Hit Papers
Peers
Comparison fields: 5 of 108
- Pulmonary and Respiratory Medicine 8.3k
- Oncology 4.7k
- Cancer Research 1.6k
- Radiology, Nuclear Medicine and Imaging 1.1k
- Otorhinolaryngology 198
Countries citing papers authored by Alison Armour
This map shows the geographic impact of Alison Armour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Armour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Armour more than expected).
Fields of papers citing papers by Alison Armour
This network shows the impact of papers produced by Alison Armour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Armour. The network helps show where Alison Armour may publish in the future.
Co-authors
The 25 scholars most cited alongside Alison Armour, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Hit paper breakdown → | 2009 | 6400 |
| 2 | Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2021 | 1582 |
| 3 | Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) Hit paper breakdown → | 2011 | 1189 |
| 4 | Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Hit paper breakdown → | 2008 | 1012 |
| 5 | Interstitial Lung Disease in Japanese Patients with Lung Cancer Hit paper breakdown → | 2008 | 368 |
| 6 | 2009 | 269 | |
| 7 | 2008 | 176 | |
| 8 | 2011 | 108 | |
| 9 | 2009 | 96 | |
| 10 | 2009 | 95 | |
| 11 | 2016 | 53 | |
| 12 | No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. | 1995 | 39 |
| 13 | 2010 | 33 | |
| 14 | 2009 | 28 | |
| 15 | 2008 | 27 | |
| 16 | 1993 | 22 | |
| 17 | 2007 | 19 | |
| 18 | A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck | 2007 | 18 |
| 19 | 2000 | 16 | |
| 20 | 2007 | 15 |
About Alison Armour
Alison Armour is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Surgery and Neurology, having authored 37 papers that have together received 11.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (19 papers), Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Research Studies (6 papers), Prostate Cancer Treatment and Research (5 papers), Radiopharmaceutical Chemistry and Applications (5 papers), Cancer Genomics and Diagnostics (3 papers), HER2/EGFR in Cancer Research (3 papers) and Mass Spectrometry Techniques and Applications (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (8.3k citations), Oncology (4.7k citations), Cancer Research (1.6k citations), Radiology, Nuclear Medicine and Imaging (1.1k citations) and Otorhinolaryngology (198 citations). Alison Armour has collaborated with scholars based in United Kingdom, United States and China. Frequent co-authors include Tony Mok, Yi‐Long Wu, Emma Duffield, Claire Watkins, Masahiro Fukuoka, Haiyi Jiang, Nagahiro Saijo, Sumitra Thongprasert, Patrapim Sunpaweravong and Yutaka Nishiwaki. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Cancer Research and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.